Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report - Poll - MDSpire

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report

  • By

  • Ruiyue Wu

  • Xi Chen

  • Tong Li

  • Yunmei Zhang

  • Xiaoling Ling

  • May 4, 2026

  • 0 min

Share

Original Source(s)

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report

  • by Ruiyue Wu, Xi Chen, Tong Li, Yunmei Zhang, Xiaoling Ling

  • May 4, 2026

Related Content

Predicting preoperative axillary lymph node metastasis to guide surgical decisions in invasive breast cancer

Synthetic short RNA in cancer

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review